RenovoRx appoints former Schering-Plough CMO Robert Spiegel to board

RenovoRx, Inc.

Dr. Spiegel appointed as independent director effective April 25, 2023; board size increased from 6 to 7.
He brings 40+ years biopharma experience, involved in over 30 FDA NDA approvals and multiple blockbuster drugs.
Received initial option award for 43,026 shares valued at $120,000, vesting monthly over 36 months.
Company plans to advance FDA discussions on RenovoGem Phase III interim data and new indications.
Dr. Spiegel also serves on boards of Geron, Cyclacel, Ayala, Athenex, and SPARC.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert Spiegel

independent director

RNXT · RenovoRx, Inc.

Effective: 2023-04-25
Filed: April 27, 2023, 7:59 PM ET

Effective as of April 25, 2023, the Board of Directors of RenovoRx, Inc. (the “Company”) appointed Robert Spiegel, M.D., FACP, to its Board of Directors as an independent director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Spiegel was appointed as independent director at RenovoRx, Inc..

Action: appointed
Role: independent director

Exact text from the filing

Effective as of April 25, 2023, the Board of Directors of RenovoRx, Inc. (the “Company”) appointed Robert Spiegel, M.D., FACP, to its Board of Directors as an independent director

View on SEC.gov

RenovoRx, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-013781

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.